CA2937088C - Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus - Google Patents

Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus Download PDF

Info

Publication number
CA2937088C
CA2937088C CA2937088A CA2937088A CA2937088C CA 2937088 C CA2937088 C CA 2937088C CA 2937088 A CA2937088 A CA 2937088A CA 2937088 A CA2937088 A CA 2937088A CA 2937088 C CA2937088 C CA 2937088C
Authority
CA
Canada
Prior art keywords
hev
virus
concentration
reaction mixture
titer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2937088A
Other languages
English (en)
French (fr)
Other versions
CA2937088A1 (en
Inventor
Brett Buno
Terri Journigan
Joann Hotta
Michael Burdick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols SA filed Critical Grifols SA
Publication of CA2937088A1 publication Critical patent/CA2937088A1/en
Application granted granted Critical
Publication of CA2937088C publication Critical patent/CA2937088C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA2937088A 2015-07-23 2016-07-22 Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus Active CA2937088C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195936P 2015-07-23 2015-07-23
US62/195.936 2015-07-23

Publications (2)

Publication Number Publication Date
CA2937088A1 CA2937088A1 (en) 2017-01-23
CA2937088C true CA2937088C (en) 2022-06-21

Family

ID=56409494

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2937088A Active CA2937088C (en) 2015-07-23 2016-07-22 Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus

Country Status (22)

Country Link
US (1) US10208291B2 (cg-RX-API-DMAC7.html)
EP (1) EP3121267B1 (cg-RX-API-DMAC7.html)
JP (1) JP6588397B2 (cg-RX-API-DMAC7.html)
KR (1) KR102154380B1 (cg-RX-API-DMAC7.html)
CN (1) CN106367397B (cg-RX-API-DMAC7.html)
AR (1) AR106015A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016204734B2 (cg-RX-API-DMAC7.html)
BR (1) BR102016016677A2 (cg-RX-API-DMAC7.html)
CA (1) CA2937088C (cg-RX-API-DMAC7.html)
CL (1) CL2016001768A1 (cg-RX-API-DMAC7.html)
ES (1) ES2669021T3 (cg-RX-API-DMAC7.html)
HU (1) HUE036699T2 (cg-RX-API-DMAC7.html)
IL (1) IL246634B (cg-RX-API-DMAC7.html)
MX (1) MX375106B (cg-RX-API-DMAC7.html)
MY (1) MY176204A (cg-RX-API-DMAC7.html)
NZ (1) NZ722213A (cg-RX-API-DMAC7.html)
PL (1) PL3121267T3 (cg-RX-API-DMAC7.html)
PT (1) PT3121267T (cg-RX-API-DMAC7.html)
RU (1) RU2691123C1 (cg-RX-API-DMAC7.html)
SG (1) SG10201605867UA (cg-RX-API-DMAC7.html)
TW (1) TWI666322B (cg-RX-API-DMAC7.html)
UY (1) UY36778A (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102158641B1 (ko) * 2019-03-06 2020-09-22 대한민국 야누스 인산화효소 저해제 및 헥사디메트린 브로마이드를 포함하는 바이러스 배양용 조성물 및 이를 이용한 바이러스 배양 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506604B2 (en) * 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6217858B1 (en) * 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
WO2003001198A1 (en) * 2001-06-21 2003-01-03 Regents Of The University Of California Immortalization of human cells by the ectopic expression of human telomerase reverse transcriptase
WO2007046962A2 (en) * 2005-09-02 2007-04-26 The University Of Maryland, Baltimore Cell lines harboring hepatitis virus and methods for using thereof
WO2010040001A1 (en) * 2008-10-03 2010-04-08 The Rockefeller University New hcv entry factor, occludin
EP2663328B1 (en) 2011-01-10 2018-09-19 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Infectious hepatitis e virus genotype 3 or 1 recombinants
DK2717922T3 (en) * 2011-06-10 2019-01-07 Bluebird Bio Inc GENERATIVE VECTORS FOR ADDRENOLEUCODYSTROPHY AND ADDRENOMYELONE EUROPE

Also Published As

Publication number Publication date
TW201704468A (zh) 2017-02-01
IL246634A0 (en) 2016-12-29
AU2016204734A1 (en) 2017-02-09
CN106367397B (zh) 2021-07-20
JP2017023143A (ja) 2017-02-02
RU2691123C1 (ru) 2019-06-11
AR106015A1 (es) 2017-12-06
CL2016001768A1 (es) 2017-05-12
NZ722213A (en) 2019-04-26
ES2669021T3 (es) 2018-05-23
HUE036699T2 (hu) 2018-07-30
BR102016016677A2 (pt) 2019-02-12
IL246634B (en) 2020-08-31
KR20170012140A (ko) 2017-02-02
PT3121267T (pt) 2018-04-26
MX375106B (es) 2025-03-06
UY36778A (es) 2016-09-30
MY176204A (en) 2020-07-24
SG10201605867UA (en) 2017-02-27
MX2016009048A (es) 2017-01-23
JP6588397B2 (ja) 2019-10-09
EP3121267A1 (en) 2017-01-25
US10208291B2 (en) 2019-02-19
KR102154380B1 (ko) 2020-09-10
AU2016204734B2 (en) 2019-11-21
EP3121267B1 (en) 2018-03-28
TWI666322B (zh) 2019-07-21
PL3121267T3 (pl) 2018-07-31
CN106367397A (zh) 2017-02-01
US20170022481A1 (en) 2017-01-26
CA2937088A1 (en) 2017-01-23

Similar Documents

Publication Publication Date Title
Rogee et al. New models of hepatitis E virus replication in human and porcine hepatocyte cell lines
Sanada et al. Transmission of HBV DNA mediated by ceramide-triggered extracellular vesicles
Ambrose et al. Virus discovery by sequence‐independent genome amplification
Sridhar et al. A systematic approach to novel virus discovery in emerging infectious disease outbreaks
Grigorov et al. Rapid titration of measles and other viruses: optimization with determination of replication cycle length
Van Baalen et al. Detection of nonhemagglutinating influenza a (h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture
Parvin et al. Differential replication properties among H9N2 avian influenza viruses of Eurasian origin
Lu et al. Development and evaluation of one-step TaqMan real-time reverse transcription-PCR assays targeting nucleoprotein, matrix, and hemagglutinin genes of equine influenza virus
Brussel et al. Use of a new RNA next generation sequencing approach for the specific detection of virus infection in cells
Zhang et al. Persistent infection with a rabbit hepatitis E virus created by a reverse genetics system
Roth et al. Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses
Cheval et al. Adventitious virus detection in cells by high-throughput sequencing of newly synthesized RNAs: unambiguous differentiation of cell infection from carryover of viral nucleic acids
Liu Molecular detection of human viral pathogens
US10208291B2 (en) Method for generating high-titer hepatitis E virus stocks and titration assay for hepatitis E virus
Liu et al. Construction and characterization of an infectious clone of coxsackievirus A16
Yang et al. Establishment and optimization of a rapid and convenient viral RNA transcript copy reduction neutralization test (VcRNT) for quantification of hantaan orthohantavirus (HTNV) neutralizing antibodies
Rivera-Benitez et al. Efficacy of quantitative RT-PCR for detection of the nucleoprotein gene from different porcine rubulavirus strains
HK1230654A1 (en) Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus
HK1230654B (en) Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus
US20100255459A1 (en) Control for virus detection assays based on reverse-transcription polymerase chain reaction
KR101310873B1 (ko) Ａ형 인플루엔자 바이러스 검출용 프라이머 세트, 상기 프라이머 세트를 포함하는 ａ형 인플루엔자 바이러스 검출용 조성물 및 키트, 및 이를 이용한 ａ형 인플루엔자 바이러스 검출 방법
Otsuki et al. Elucidation of the full genetic information of Japanese rubella vaccines and the genetic changes associated with in vitro and in vivo vaccine virus phenotypes
CN108055827A (zh) 高成长肠病毒71型病毒株及其疫苗
Lee et al. M‐specific reverse transcription loop‐mediated isothermal amplification for detection of pandemic (H1N1) 2009 virus
CN110846437A (zh) 鸡细小病毒与h9亚型禽流感病毒二重pcr检测引物组、试剂盒及方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190225

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250626

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250626